PSTV Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Plus Therapeutics Inc (PSTV) is not a strong buy for a beginner investor with a long-term strategy at this time. The stock's recent reverse split, declining financial performance, and lack of significant positive trading trends or proprietary trading signals make it a risky investment. While there are some positive developments in its clinical pipeline and Nasdaq compliance, the elevated capital risk profile and weak analyst sentiment suggest a cautious approach.
The MACD is positive but contracting, suggesting weakening bullish momentum. RSI is in the neutral zone, indicating no clear overbought or oversold conditions. Moving averages are converging, showing no strong trend. The stock is trading near its resistance level (R1: 7.622), which may limit further upside in the short term.
The company has regained Nasdaq compliance, partnered with SpectronRx to enhance supply chain reliability, and appointed a new Chief Development Officer to improve R&D capabilities in CNS cancers.
The recent 1-for-25 reverse stock split indicates capital market strain and may pressure trading liquidity. Analysts have downgraded the stock and lowered price targets due to elevated capital risk and lower liquidity. Financial performance shows declining revenue and EPS, despite improved net income.
In 2025/Q4, revenue dropped by 3.19% YoY, and EPS fell by 92.00% YoY, indicating weak operational performance. However, net income improved by 46.37% YoY, driven by cost management. Gross margin remains at 100%, showing strong profitability on existing revenue.
Analysts have mixed views but lean negative. Maxim lowered the price target to $12 from $37.50, citing elevated capital risk. D. Boral Capital downgraded the stock to Hold, highlighting the negative implications of the reverse stock split. Lake Street initiated coverage with a Buy rating and a $2 price target, citing potential synergies in the company's CNS cancer pipeline.
